SARS-CoV-2: recommendations for treatment in intensive care medicine
Markus Köstenberger(Klinikum Klagenfurt), Rudolf Likar(Klinikum Klagenfurt), Christoph Hörmann(Universitätsklinikum St. Pölten), Michael Joannidis(Innsbruck Medical University), Klaus Markstaller(Medical University of Vienna), Thomas Staudinger(Northwestern University), Roman Ullrich(University of Vienna), Eva Schaden(Medical University of Vienna), Steve-Oliver Müller-Muttonen, Stefan Neuwersch-Sommeregger(Klinikum Klagenfurt), Daniel Dankl(Unfallkrankenhaus Salzburg), Walter Hasibeder(Gesundheit Österreich), Reinhard Germann(Landeskrankenhaus Feldkirch), Andreas Valentin(Schwarzwald-Baar Klinikum)
Cited by 9
Related Papers
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
|Critical Care|2013|1.4k
Clinical practice guideline on diagnosis and treatment of hyponatraemia
|Intensive Care Medicine|2014|1k
Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest
|New England Journal of Medicine|2021|979
A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study
|Intensive Care Medicine|2009|906
Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies
|The Lancet Infectious Diseases|2013|876